Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4192—1,2,3-Triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4196—1,2,4-Triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

• the invention is concerned with novel substituted piperidine derivatives of the formula (I)
• the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
• CPT1 the outer mitochondrial membrane enzyme, catalyzes the formation of long-chain acylcarnitines.
• Liver (L-CPT1) and muscle (M-CPT1) CPT1 isoforms are encoded by two different genes and inhibited by malonyl-CoA.
• the N-ter domain of L-CPT1 confers its lower sensitivity to malonyl CoA.
• CPT2 the inner mitochondrial membrane enzyme, reconverts long-chain acylcarnitines into long-chain acyl CoA esters. Long-chain acyl-CoAs are then ⁇ -oxidized to acetyl-CoA, which activates the pyruvate carboxylase and gluconeogenesis. According to the mechanism of action described above, pharmaceutically active substances which inhibit L-CPT1 reduce liver ⁇ -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia.
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and X are as defined in the compound of formula (I) and L is halogen.
• a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I) and a pharmaceutically acceptable carrier and/or adjuvant.
• a method for the treatment of diseases which are modulated by L-CPT1 inhibitors comprising the step of administering a therapeutically effective amount of a compound according to formula (I) to a human being or animal in need thereof.
• the present invention relates to novel compounds which inhibit liver carnitine palmitoyl transferase 1 (L-CPT1) activity.
• the compounds of the present invention can be used as pharmaceutically active agents which are useful in the prevention and/or treatment of diseases which are modulated by L-CPT1 inhibitors, particularly diseases which are related to hyperglycemia and/or glucose tolerance disorders.
• diseases include e.g. diabetes and associated pathologies, non insulin dependent diabetes mellitus (also referred to as diabetes type II), obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.
• lower is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).
• halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
• alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.
• lower-alkyl refers to a branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
• hydroxy-lower-alkyl refers to a lower-alkyl group which is substituted with hydroxy.
• fluoro-lower-alkyl refers to lower-alkyl groups which are mono- or multiply substituted with fluorine.
• fluoro-lower-alkyl groups are e.g. CFH 2 , CF 2 H, CF 3 , CF 3 CH 2 , CF 3 (CH 2 ) 2 , (CF 3 ) 2 CH and CF 2 H—CF 2 .
• alkoxy refers to the group R′—O—, wherein R′ is an alkyl.
• lower-alkoxy refers to the group R′—O—, wherein R′ is a lower-alkyl.
• fluoro-lower-alkoxy refers to the group R′′—O—, wherein R′′ is fluoro-lower-alkyl.
• fluoro-lower-alkoxy groups are e.g. CFH 2 —O, CF 2 H—O, CF 3 —O, CF 3 CH 2 —O, CF 3 (CH 2 ) 2 —O, (CF 3 ) 2 CH—O, and CF 2 H—CF 2 —O.
• alkenyl stands for a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 20, preferably up to 16 carbon atoms.
• lower-alkenyl refers to a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl.
• alkinyl stands for a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 20, preferably up to 16 carbon atoms.
• lower-alkinyl refers to a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propinyl.
• alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkylene groups as described below also are preferred alkylene groups.
• lower-alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.
• cycloalkyl refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
• aryl alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be substituted by 1 to 5, preferably 1 to 3, substituents independently selected from the group consisting of halogen, hydroxy, amino, NO 2 , lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy, carboxy, carboxy-lower-alkyl, lower-alkoxy-carbonyl, lower-alkoxy-carbonyl-lower-alkyl, lower-alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkylcarbonyl-NH, H 2 NC(O), (H,lower-alkyl)NC(O), (lower-alkyl) 2 NC(O), H 2 NC(O)-lower-alkyl, (H,lower-alkyl)NC(O)-lower-alkyl, (lower-alkyl) 2 NC(O)-lower-alkyl
• a benzodioxyl group cyano, heteroaryl, cycloalkyl, lower-alkoxy-lower-alkyl, lower-alkenyl, lower-alkinyl, phenyl and phenyloxy.
• substituents halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and fluoro-lower-alkoxy are preferred.
• aryl groups can be substituted as described in the description below.
• heteroaryl refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzimidazolyl, indolyl, indazolyl, benzoisothiazolyl, benzoxazolyl, benzoisoxazolyl, pyridinyl-2-one, oxadiazolyl, 1,3-dihydro-benzimidazol-2-
• heteroaryl 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one.
• a heteroaryl group may optionally have a substitution pattern as described earlier in connection with the term “ary
• heterocyclyl refers to 5 to 6 membered monocyclic ring or 8 to 14, preferably 8 to 10, membered bi- or tricyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperazinyl and pyrrolidinyl.
• heterocyclyl 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one, 1,3-dihydro-imidazol-2-one, thiazolidinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl.
• a heterocyclyl may optionally have a substitution pattern as described earlier in connection with the term “aryl”.
• heterocyclyl groups can preferably be substituted as described in the description below.
• compositions of formula (I) wherein an amino group is present can form pharmaceutically acceptable acid addition salts.
• pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
• physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid
• organic acids such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
• Compounds of formula (I) in which a COOH group is present can further form salts with bases.
• Examples of such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na—, K—, Ca— and Trimethylammonium salt.
• the term “pharmaceutically acceptable salts” also refers to such salts. Salts obtained by the addition of an acid are preferred.
• esters embraces derivatives of the compounds of formula (I), in which a carboxy group has been converted to an ester.
• esters are preferred esters.
• pharmaceutically acceptable esters furthermore embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.
• the compounds of formula (I) can have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, mixture of stereoisomers or as optically pure compounds.
• Preferred compounds of formula (I) as described above are those, wherein
• Preferred compounds of formula (I) as described above are those, wherein R 1 is phenyl optionally substituted with halogen, hydroxy, hydroxy-lower-alkyl or CN, more preferably those wherein R 1 is phenyl.
• R 2 is hydrogen.
• R 3 is hydrogen.
• R 4 is hydrogen.
• R 5 is hydrogen.
• Compounds wherein R 6 is hydrogen are alo preferred.
• R 7 which are an oxadiazolyl are not substituted with R 12 .
• R 7 is
• R 11 and R 12 are as defined above.
• R 7 is
• R 11 and R 12 are as defined in claim 1 .
• R 7 is
• R 11 is as defined above.
• Preferred compounds of formula (I) as described above are those, wherein X is C(R 8 R 9 ), NR 10 , O or S, wherein R 8 , R 9 and R 10 are as defined above.
• X is C(R 8 R 9 ) or NR 10 , wherein R 8 , R 9 and R 10 are as defined above.
• R 8 is hydrogen.
• R 9 is hydrogen.
• R 10 is hydrogen.
• R 11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl and benzimidazolyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O 2 )R 13 , C(O)R 14 , NO 2 , NR 15 R 16 , imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, and phenyl-lower-alkoxy, which imidazolyl is
• R 11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl and benzimidazolyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of fluoro-lower-alkyl, halogen, C(O)R 14 and NR 15 R 16 , wherein R 14 , R 15 and R 16 are as defined above.
• R 11 is 1H-Indazol-5-yl, 1H-Indazol-6-yl, 1,3-dihydro-indol-2-one-6-yl, 1,3-dihydro-benzoimidazol-2-one-5-yl, 1,3-dihydro-indol-2-one-5-yl, 1H-Benzotriazol-5-yl, 1H-Benzoimidazol-5-yl, 1H-pyridin-2-one-4-yl, 4-Fluoro-phenyl, 3-trifluoromethyl-phenyl, 1H-Benzoimidazol-5-yl, 3-benzamide, 5-nicotinamide, 3-(N-acetamide)-phenyl or 3-(N-methanesulfonamide)-phenyl.
• R 11 is phenyl or a heteroaryl selected from the group consisting of 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-
• R 11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, 1,3-dihydro-indol-2-one, 1H-benzimidazolyl, 3H-pyrimidin-4-one, 1H-pyrazolyl, isoxazolyl and 4H-benzo[1,4]oxazin-3-one, which phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy, halogen and NR 15 R 16 , wherein R 14 and R 15 are as defined in claim 1 .
• R 11 is 2-methyl-3H-pyrimidin-4-one, 5-methyl-isoxazol-3-yl, 1H-pyrazol-3-yl, 6-amino-pyridin-3-yl, 1,3-dihydro-indol-2-one, 2-amino-pyridin-4-yl, 4H-benzo[1,4]oxazin-3-one, 1H-benzimidazol-5-yl, 3-(N-acetamide)-4-fluoro-phenyl or 2-hydroxy-pyridin-4-yl.
• R 12 is hydrogen.
• R 13 is lower-alkyl
• R 14 is NR 19 R 20 , wherein R 19 and R 20 are as defined above.
• R 14 is lower-alkyl.
• R 15 and R 16 independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO 2 , lower-alkenyl-oxy-carbonyl or lower-alkyl-NH-carbonyl; or NR 15 R 16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, piperazinyl and pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl. More preferably, R 15 and R 16 independently from each other are hydrogen, lower-alkyl-carbonyl or lower-alkyl-SO 2 .
• NR 15 R 16 is a heterocyclyl selected from the group consisting of 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl.
• R 17 and R 18 independently from each other are hydrogen or lower-alkyl; or NR 17 R 18 is morpholinyl.
• R 19 and R 20 independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or NR 19 R 20 is a heterocyclyl selected from the group consisting of morpholinyl or pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy or lower-alkyl-S(O 2 ). More preferably, R 19 and R 20 are hydrogen.
• R 19 and R 20 independently from each other are (lower-alkyl) 2 N-lower-alkyl, pyridinyl-lower-alkyl or cyano-lower-alkyl; or NR 19 R 20 is a heterocyclyl selected from the group consisting of piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl, which heterocyclyl is optionally substituted with hydroxy, lower-alkyl-S(O 2 ), lower-alkyl, lower-alkyl-carbonyl, carboxy, carbamoyl, lower-alkoxy-carbonyl, cyano, phenyl, pyridinyl or lower-alkoxy.
• Preferred compounds of formula (I) as defined above are those, which are R-isomers and which are characterised by formula (Ia)
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined above.
• preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts as well as pharmaceutically acceptable esters thereof.
• Preferred compounds of formula (I) are those selected from the group consisting of:
• Particularly preferred compounds of formula (I) are those selected from the group consisting of:
• the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
• the invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises reacting a compound of formula (II)
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and X are as defined in any of claims 1 - 22 and L is halogen.
• reaction of a compound of formula (II) with a compound of formula (III) can be carried out under conditions well known to the person skilled in the art. Such reactions can conveniently be carried out for example by mixing a compound of formula (II) with e.g. an acid chloride of formula (III) or alternatively with an activated ester thereof a compound of formula (III) in a solvent such as e.g. DMF at appropriate temperatures between 25° C. and 120° C., optionally in the presence of diisopropylethylamine.
• a solvent such as e.g. DMF
• L is Cl.
• L can be an active ester.
• Such active esters as well as their use to form amide bonds are well known to the person skilled in the art.
• the present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.
• the carboxylic acid analogues were generated from the corresponding esters through classical saponification with NaOH or LiOH or by catalytic debenzylation procedures where the starting material is typically dissolved in methanol and an aqueous solution of NaOH or LiOH is added.
• the reaction is stirred preferably for 2 h at room temperature and the product extracted form ethylacetate/water after acidification of the reaction mixture.
• the carboxyamide analogues were generated from the corresponding carboxylates by preactivation with reagents such as TBTU in DMF.
• the reaction mixtures are usually stirred at room temperature overnight.
• the primary carboxyamide analogues were generated from the corresponding carboxylates through coupling on Rink-resin and subsequent cleavage with TFA by preactivating the starting material with reagents such as TBTU.
• the reaction mixture is usually stirred at room temperature overnight. After excessive washing of the resins with solvents such as DMF, methanol and methylenchloride the solid phase material is treated with TFA at room temperature for 2 h. After evaporation the product is isolated by chromatography.
• the amino derivatives were generated from the corresponding nitro analogues through a Zink mediated reduction where the starting material is dissolved preferably in ethanol and saturated aqueous ammonium chloride. An excess of zinc powder is added, the reaction briefly heated to reflux and then stirred at room temperature for 16 h. The product is isolated by extraction from ethylacetate/water and final chromatography
• N-amides, -sulfonamides, -carbamates and -ureas were all generated from the corresponding amino-derivatives where the amino-derivatives are dissolved preferably in DMF and the corresponding acetyl chlorides or activate esters, sulfonyl chlorides or isocyanates are added.
• the reactions proceed at room temperature.
• the products are isolated by chromatography.
• the benzonitriles were generated from the corresponding primary benzamides by treatment of the latter with neat trifluoroacetic anhydride at room temperature for preferably 16 h.
• the non-commercially available aminoacids were generated from Piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester by coupling with either acetyl chloride or methylsulfonyl chloride in THF at room temperature followed by saponification as described above.
• hydroxyamidines were generated from the corresponding nitriles by the addition of 5 equivalents of hydroxylamine mono hydrochloride and 2.5 equivanents sodium carbonate in a mixture of ethanol/water (7:3).
• the reaction mixture was heated to 80° C. for usually 2 h.
• the product was isolated by extraction from ethylacetate/water.
• the non-commercially available sulfonamido hydroxyamidines were generated by coupling of 4-cyanobenzen-1-sulfonylchloride with 2 equivalents of the corresponding amine in THF at room temperature for 16 h. After evaporation of the solvent the product is extracted from ethylacetate/water. The crude nitril is treated with hydrazine as described above.
• the non-commercially available 2-aminopyridino hydroxyamidines were generated from the corresponding nitrites as described above.
• the nitriles were obtained from the corresponding chlorocyanopyridines after dissolving in DMF and adding 2 equivalents of the amine.
• the reaction mixture was heated to 120° C. under microwave conditions usually for 30 min.
• the product was isolated by extraction from ethylacetate/water after evaporation of the reaction solvent.
• the aminoamidines were generated from the corresponding imidoethers by addition of 1 equivalent of hydrazine monohydrate in methanol. The product was isolated by precipitation when adding 1.25M HCl/methanol. The iminoethers were obtained from the corresponding nitriles after suspending in methylenchloride and saturation with HCl gas at 0° C. for 30 min. The reaction mixture was stirred for 16 h at room temperature and the product filtered off after addition of diethylether.
• the non-commercially available nitrites were generated from the corresponding primary amides by the addition of neat trifluoroaceticacid anhydride at room temperature preferably for 16 h.
• compounds of general formula 1 can be dissolved preferably in DMF and 1 equivalent of activation reagent such as TBTU is added in addition to 1 equivalent of a base such as DIPEA.
• activation reagent such as TBTU
• a base such as DIPEA
• the reaction is cooled to 0° C. and an excess of hydrazine added.
• the reaction is warmed up and stirred at ambient temperature to result in compound 2.
• Catalytic amount of acetic acid is added and the reaction heated to 120° C. overnight to result in compounds of general formula 4.
• compound 1 can be dissolved preferably in aqueous ethanol and treated with an excess of hydrazine hydrochloride and a base such as sodium carbonate to result in compound 2.
• This intermediate can be coupled with 1 equivalent of pre-activated carboxylates or their corresponding acetyl chlorides in solvents such as DMF to result in compounds with the general formula 3.
• Cyclisation to the corresponding oxadiazole occurs under elevated temperature either using conventional or microwave heating. Boc cleavage is usually performed using either neat TFA or 4N HCl in Dioxan to result in compounds of general formula 5.
• the final product is obtained by treating these intermediates either with phenoxyacetyl chloride and derivatives thereof or its corresponding active esters.
• the corresponding salts can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula(I) in a suitable solvent such as e.g. dioxan or THF and adding an appropriate amount of the corresponding acid.
• a suitable solvent such as e.g. dioxan or THF
• the products can usually be isolated by filtration or by chromatography.
• the conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of a suitable carboxy group present in the molecule with a suitable alcohol using e.g. a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N-dicyclohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) or O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TPTU).
• a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N
• the novel compounds of the present invention have been found to inhibit liver carnitine palmitoyl transferase 1 (L-CPT1) activity.
• the compounds of the present invention can therefore be used in the treatment and/or prophylaxis of diseases which are modulated by L-CPT1 inhibitors, particularly diseases which are related to hyperglycemia and/or glucose tolerance disorders.
• diseases include e.g. diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.
• the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
• the invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by L-CPT1 inhibitors, particularly as therapeutically active substances for the treatment and/or prophylaxis of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.
• the invention relates to a method for the therapeutic and/or prophylactic treatment of diseases which are modulated by L-CPT1 inhibitors, particularly for the therapeutic and/or prophylactic treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure, which method comprises administering a compound as defined above to a human being or animal.
• the invention also embraces the use of compounds as defined above for the therapeutic and/or prophylactic treatment of diseases which are modulated by L-CPT1 inhibitors, particularly for the therapeutic and/or prophylactic treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.
• the invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by L-CPT1 inhibitors, particularly for the therapeutic and/or prophylactic treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.
• Such medicaments comprise a compound as described above.
• Human liver and muscle CPT1 cDNAs and rat CPT2 cDNA were subcloned in pGAPZB or pGAPZA, respectively. These plasmids were used to transform P. pastoris strain X-33 via electroporation after the preparation of electrocompetent cells. High copy number clones were selected where necessary using 0.5 or 1 mg/ml Zeocin. Cultures for activity measurements were induced for 16 h in YPD medium (1% yeast extract, 2% peptone, 2% glucose). Crude cell extracts were prepared by disrupting the cells with glass beads or French Press, depending on fermenter sizes.
• cell breaking buffer 50 mM Tris, pH7.4, 100 mM KCl, 1 mM EDTA
• protease inhibitor cocktail 50 mM Tris, pH7.4, 100 mM KCl, 1 mM EDTA
• CPT activity was measured using a spectrophotometric assay using 5,5′-dithio-bis-(2-nitrobenzoic acid) (DTNB) also called Ellman's reagent.
• DTNB 5,5′-dithio-bis-(2-nitrobenzoic acid)
• the HS-CoA released on the formation of acylcarnitine from carnitine (500 ⁇ M) and palmitoyl-CoA (80 ⁇ M) reduced DTNB (300 ⁇ M) forming 5-mercapto-(2-nitrobenzoic acid) which absorbed at 410 nm with a molar coefficient extinction of 13600 M ⁇ 1 .cm ⁇ 1 .
• the assay buffer contained 120 mM KCl, 25 mM Tris, pH 7.4, 1 mM EDTA. This assay was used for the identification of selective inhibitors of the liver CPT1 isoform versus the muscle CPT1 and CPT2 isoforms.
• the compounds according to formula (I) preferably have an IC50 value below 10 ⁇ M, preferably 10 nM to 10 ⁇ M, more preferably 10 nM to 5 ⁇ M.
• the following table shows data for some examples.
• the compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
• the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
• Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
• lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules.
• Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
• Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
• Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
• Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
• Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
• Usual stabilizers preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
• the dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 2000 mg, especially about 1 to 500 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
• the pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-200 mg, of a compound of formula I.
• Crude material from step 1 was either treated at 80° C. for 16 h or briefly heated to 120° C. under microwave conditions (10 min). The DMF was evaporated and the product extracted from ethylacetate/water. The product was not further characterized.
• Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
• Kernel Compound of formula (I) 10.0 mg 200.0 mg Microcrystalline cellulose 23.5 mg 43.5 mg Lactose hydrous 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg Magnesium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg 350.0 mg Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxyde (yellow) 0.8 mg 1.6 mg Titan dioxide 0.8 mg 1.6 mg
• the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
• the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
• the kernels are lacquered with an aqueous solution/suspension of the above mentioned film coat.
• Capsules containing the following ingredients can be manufactured in a conventional manner:
• the components are sieved and mixed and filled into capsules of size 2.
• Injection solutions can have the following composition:
• the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
• the pH is adjusted to 5.0 by Acetic Acid.
• the volume is adjusted to 1.0 ml by addition of the residual amount of water.
• the solution is filtered, filled into vials using an appropriate overage and sterilized.
• Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
• Capsule contents Compound of formula (I) 5.0 mg Yellow wax 8.0 mg Hydrogenated Soya bean oil 8.0 mg Partially hydrogenated plant oils 34.0 mg Soya bean oil 110.0 mg Weight of capsule contents 165.0 mg Gelatin capsule Gelatin 75.0 mg Glycerol 85% 32.0 mg Karion 83 8.0 mg (dry matter) Titanium dioxide 0.4 mg Iron oxide yellow 1.1 mg
• the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
• the filled soft gelatin capsules are treated according to the usual procedures.
• Sachets containing the following ingredients can be manufactured in a conventional manner:
• the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
• the granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Obesity (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Epidemiology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Child & Adolescent Psychology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=37719360

Family Applications (1)

Country Status (20)

Cited By (8)

Families Citing this family (65)

Citations (3)

Family Cites Families (4)

• 2006
  • 2006-11-22 EP EP06819660A patent/EP1959951B1/en not_active Not-in-force
  • 2006-11-22 RU RU2008126398/04A patent/RU2396269C2/ru not_active IP Right Cessation
  • 2006-11-22 JP JP2008542722A patent/JP4855478B2/ja not_active Expired - Fee Related
  • 2006-11-22 PT PT06819660T patent/PT1959951E/pt unknown
  • 2006-11-22 DK DK06819660.9T patent/DK1959951T3/da active
  • 2006-11-22 CN CN2006800453448A patent/CN101321525B/zh not_active Expired - Fee Related
  • 2006-11-22 BR BRPI0619086-3A patent/BRPI0619086A2/pt not_active IP Right Cessation
  • 2006-11-22 AU AU2006319247A patent/AU2006319247B2/en not_active Ceased
  • 2006-11-22 CA CA2630460A patent/CA2630460C/en not_active Expired - Fee Related
  • 2006-11-22 WO PCT/EP2006/068745 patent/WO2007063012A1/en active Application Filing
  • 2006-11-22 DE DE602006011363T patent/DE602006011363D1/de active Active
  • 2006-11-22 PL PL06819660T patent/PL1959951T3/pl unknown
  • 2006-11-22 KR KR1020087015998A patent/KR101135310B1/ko not_active IP Right Cessation
  • 2006-11-22 ES ES06819660T patent/ES2335698T3/es active Active
  • 2006-11-22 AT AT06819660T patent/ATE452635T1/de active
  • 2006-11-29 AR ARP060105273A patent/AR056821A1/es unknown
  • 2006-11-29 US US11/605,904 patent/US7645776B2/en not_active Expired - Fee Related
  • 2006-11-29 TW TW095144178A patent/TWI358409B/zh not_active IP Right Cessation
• 2008
  • 2008-05-21 ZA ZA200804393A patent/ZA200804393B/xx unknown
  • 2008-05-26 NO NO20082388A patent/NO20082388L/no not_active Application Discontinuation

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events